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a b s t r a c t
Hypothesis: One of the main challenges in cancer therapy is the poor water solubility of many anticancer
drugs which results in low bioavailability at the tumour sites and reduced efficacy. The currently avail-
able polymer-based anticancer drug delivery systems often suffer from low encapsulation efficiency,
uncontrolled release, and lack of long-term stability. Herein, we report the development of novel
stiffness-tuneable core–shell nanocarriers composed of naturally derived polymers silk fibroin (SF) and
sodium alginate (SA) inside a liposomal shell for enhanced cellular uptake and controlled release of
hydrophobic anticancer agent ASC-J9 (Dimethylcurcumin). It is anticipated that the stiffness of the
nanocarriers has a significant effect on their cellular uptake and anticancer efficacy.
Experiments: The nanocarriers were prepared by thin film hydration method followed by extrusion and
cross-linking of SA to obtain a uniform size and shape, avoiding harsh processing conditions. The struc-
tural transformation of SF in the nanocarriers induced by SA crosslinking was determined using Fourier
transform infrared (FTIR) spectroscopy. The size, zeta potential, morphology and stiffness of the nanocar-
riers were measured using dynamic light scattering (DLS), transmission electron microscopy (TEM) and
atomic force microscopy (AFM). Drug loading and release were measured using UV–Vis spectrophotom-
etry. The cellular uptake and anticancer efficacy of the nanocarriers were studied in HCT 116 human col-
orectal adenocarcinoma cells and 3D tumour spheroids using high content microscopy.
Findings: The synthesized nanocarriers had high encapsulation efficiency (62–78%) and were physically
stable for up to 5 months at 4C. The release profile of the drug from the nanocarriers was directed by
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their stiffness and was easily tuneable by changing the ratio of SF to SA in the core. Furthermore, the
designed nanocarriers improved the cellular uptake and anticancer activity of ASC-J9, and enhanced its
tumour penetration in HCT 116 3D colorectal cancer spheroids. These findings suggest that the designed
core–shell nanocarriers can be used as a highly efficient drug delivery system for cancer therapy.
 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
One of the main obstacles to overcome in cancer therapy is
designing non-toxic and biodegradable carriers for safe and effi-
cient anticancer drug delivery. Recent advances in nanotechnology
and polymer engineering have opened doors to new and more effi-
cient approaches to cancer therapy using nano-formulations [1–3].
However, the inherent low solubility of many anticancer agents in
water and biological fluids complicates their formulation process
and hinders their clinical applications [4–6]. Moreover, low local
concentration of these drugs in the tumour tissue due to insuffi-
cient diffusion and/or short elimination half-life (t1/2) may result
in multidrug resistance (MDR) which is one of the major challenges
in cancer treatment especially in the case of metastatic cancers
such as breast and colon cancers [7–10]. For example, t1/2 of the
hydrophobic anticancer agent ASC-J9 was found to be less than 6
h following an intravenous injection in mouse, which reduces the
bioactivity in certain tissues [11]. Increasing the exposure time of
ASC-J9 to the cancer cells reduces the half maximal inhibitory con-
centration (IC50) values due to the cumulative cytotoxic effect [12].
Therefore, the development of novel drug delivery systems (DDSs)
for efficient loading, enhanced aqueous solubility, and improved
cellular uptake of hydrophobic anticancer agents within the elim-
ination time window has received more attention over the past
decade [13–15].
In order to design effective nano-carriers, several factors must
be taken into consideration such as size, geometric shape, elastic-
ity, and surface charge [16–20]. Recently, nanoformulations, such
as liposomes / lipid nanoparticles [21,22], micelles [19], polymer
conjugates, and polymeric nanoparticles [14], have been prepared
to function as vectors for many hydrophobic anticancer agents
showing great potential for delivering these agents to the target
cells [15,23]. Although engineered nanoparticles with optimized
size and shape can improve drug delivery, they still lack efficient
targeting and their accumulation in the tumour tissue is limited
to less than 1% [24]. Other limitations of the conventional nano-
carriers include low encapsulation efficiency (EE), uncontrolled
release, ‘‘initial burst effect” (rapid release of the loaded drug
within the first few minutes) and lack of long-term stability
[19,25,26]. Most of the currently available literature has focused
on improving the properties of the nanoparticles and nanolipo-
somes through modifying their surface or their outer shell respec-
tively [22,27] and only few recent studies have investigated the
impact of modifying the physical characteristics of the particle core
on their properties such as EE, release profile, and cellular uptake.
In the present work, we present novel nanocarriers with tuneable
physical properties through incorporation of a combination of silk
fibroin (SF) and sodium alginate (SA) cores in the liposomal shells.
Unlike the previous studies, the focus is on modification of the
physical properties of the core in order to enhance the EE, improve
the cellular uptake and achieve controlled drug release.
SF obtained from cocoons of bombyx mori silkworm is an FDA
approved naturally derived biopolymer which exhibits unique fea-
tures such as biocompatibility, biodegradability, and the ability to
enhance the stability of the loaded drug [28–30]. SF can undergo
diverse structural transformations at the molecular level. The most
studied transformation is the shift in the ratio of a-helix to b-sheet
[31]. This transformation results in insolubilizing SF to form micro
and nanoformulations that can be employed for drug and gene
delivery [28]. Furthermore, SF can be easily processed by various
techniques to prepare a variety of micro and nanostructures includ-
ing sponges, microspheres, nanogels, and nanoparticles for biomed-
ical applications [32]. The physical properties of silk can be
improved by blending it with other polymers. A recent study by
De Moraes et al. [33] has reported modified physical characteristics
of SF when blended with polysaccharides such as SA [33]. SF/SA
blends have almost no toxicity, high miscibility, less heterogenicity
and restricted phase separation due to the interaction between SA
carboxyl groups and SF amino groups [33]. Furthermore, mixing
SA with SF allows SF to shift to b-sheet predominant form (Silk II)
which can provide a platform for loading poorly water-soluble
compounds through hydrophobic interactions [28,33]. Therefore,
the combination of SF and SA has been selected in this study to form
the core of the nanocarriers. This combination of polymers also
allows for controlling the elasticity of the nanocarriers.
Particle elasticity hypothesis has drawn increasing attention in
the field of nanomedicine in the past few years [34]. Modifying the
rigidity of the nanoparticles can alter their cellular uptake path-
ways (e.g. fusion and/or endocytosis), as well as other properties
such as EE and drug release [20,35–37]. For example, Sun et al.
[36] developed modified PLGA-lipid nanoparticles with different
rigidity by altering the injection order of PLGA and PEG-lipid solu-
tions in the microfluidic system to vary the amounts of water in
between the polymeric core and the lipid shell [36]. However, this
method employed synthetic polymers and organic solvents which
is not desirable for biomedical applications. In a more recent study
conducted by Guo et al. [35] the elasticity of the crosslinked nano-
gel cores was altered by changing the crosslinker concentration
[35]. In the present study, nanocarriers consisting of a lipid shell
and a core composed of a combination of SF and SA have been
developed using a simple procedure that does not require any
organic solvents, synthetic polymers or high concentrations of
the crosslinkers, and used for delivery of highly hydrophobic anti-
cancer agent ASC-J9 to HCT 116 colorectal adenocarcinoma cells.
ASC-J9 has been used for the treatment of different types of cancer
including prostate cancer and breast cancer due to its ability to
enhance the degradation of androgen receptors (AR) and increase
the downstream apoptotic markers [12,14]. However, there are
no reports of the use of ASC-J9 for the treatment of colorectal can-
cer. The stiffness of the designed nanocarriers was simply tuned by
changing the ratio between SF and SA. To the best of our knowl-
edge, using the combination of SF and SA for tuning the stiffness
of the nanocarriers, regulating their cellular uptake and drug
release has not been reported elsewhere.
2. Materials and methods
2.1. Materials
Bombyx mori silk was obtained from Jiangsu, P.R. China. Sodium
carbonate (99% pure) was purchased from Alfa Aesar. 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC, 99% pure) was purchased
from Avanti Polar Lipids, US. Dimethylcurcumin (ASC-J9, 98% pure)
was provided by Changzhou University, China. Sodium alginate
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(C6H9NaO7, 99% pure), sodium salicylate (C7H5NaO3, 99% pure),
calcium chloride (CaCl2, 93% pure) and foetal bovine serum (FBS)
were purchased from SIGMA-ALDRICH, Gillingham, UK. DMEM
(Dulbecco’s Modified Eagle Medium) and Hoechst 33,342 (99%
pure) were purchased from Thermo Fisher Scientific. Flash Phal-
loidinTM 594 was purchased from Biolegend.
2.2. Preparation of SF and SA solutions
To extract the SF, the silk cocoons were boiled in 0.02 M sodium
carbonate solution for 30 min and rinsed in DI water to remove any
traces of the dissolved sericin. After drying, the degummed fibres
of SF were dissolved in Ajisawa’s reagent (CaCl2/ ethanol/ water = 1:
2: 8 M ratio) at 80 C for 90 min followed by dialysis in a cellulose
tube (FLOAT-A-LYZER G2 dialysis tubing MWCO 12 kDa, Spectrum
Labs, Rancho Dominguez, CA, USA) against DI water for 2 days to
remove CaCl2 and ethanol. The solution was then centrifuged at
12,000 rpm and filtered through a 0.45 mm filter. The SA solution
was prepared by dissolving SA powder in DI water (20 mg/mL) at
30 C and kept on constant stirring overnight.
2.3. Synthesis and characterization of the SF/SA incorporated
nanocarriers
DOPC (10 mg) was dissolved in chloroform (1 mL) in a round
bottom flask. The solvent was evaporated using a rotary evaporator
to form a thin layer of lipid which was then hydrated with 1 mL of
SF/SA mixture (with different ratios for each formulation) at 35 C
for 10–15 min to formmultilamellar lipo-gel vesicles (MLV). Unen-
capsulated SF/SA was removed using 30 k Amicon Ultra Centrifugal
Filters at 5,000 rpm for 15 min. MLVs were extruded through a
200 nm polycarbonate membrane (Avanti Mini-Extruder) 8 times
to form small uniform nanocarriers.
2.4. Preparation of ASC-J9 loaded nanocarriers
Three formulations of nanocarriers containing different ratios of
the biopolymers (SF:SA 7:3, 1:1, 3:7)were prepared and loadedwith
the hydrophobic anticancer drug ASC-J9. The drug loading and
crosslinking of the SAmonomerswithin the biopolymeric corewere
performed simultaneously by adding ASC-J9 and CaCl2 (10 mM)
dropwise to the nanocarrier solutions (1:1, v:v). After 1 h incubation
with constant stirring at 30 C, the crossed-linked nanocarrierswere
dialyzed in FLOAT-A-LYZER G2 dialysis tubing (MWCO 1000 kDa) in
PBS for 8 h at 4 C to remove the remaining CaCl2.
2.5. Encapsulation efficiency measurement
Tomeasure the EE, the unencapsulated drugwas removed by gel
filtration using Sephadex G50 in an HR 10/30 columnwith DI water
as eluent at a flow rate of 1 mL/min. Next, 50 mL of the sample was
diluted with DMSO in an eppendorf tube and vortexed for 1 min.
The encapsulated drug was quantified by UV–Vis spectrophotome-
try (JENWAY 6715, Bibby Scientific, UK) at 435 nm using standard
calibration curves for ASC-J9 in DMSO and PBS. Each sample was
assayed in triplicate. The EE% was determined by Equation (1):
EE% ¼
Encapsulated ASC  J9
Initally added ASC  J9
 100% ð1Þ
2.6. Nanocarrier characterization
2.6.1. Particle size and zeta potential measurement
The size and Zeta potential of the different formulated nanocar-
riers were measured in PBS (pH 7.4) using dynamic light scattering
(DLS) (NanoBrook 90 plus Pals Particle size Analyzer, Brookhaven
Instrument, NY, USA). The temperature was set at 20 C and the
diode laser with a wavelength of 660 nm was used.
2.6.2. Fourier transform infrared spectroscopy
Fourier transform infrared (FTIR) spectroscopy (IR Prestige-21,
Shimadzu, UK) was used to investigate the chemical interaction
between SF and SA and to detect the SF structural transformations.
Nanocarrier formulations were mixed with 1% triton X-100 to dis-
turb the lipid shell and then centrifuged using 30 k Amicon Ultra
Centrifugal Filters at 10,000 rpm to remove the remaining lipid.
The samples were allowed to air dry on the diamond attenuated
total reflectance (ATR) attachment (ATR apparatus, Pike Technolo-
gies, USA) of the spectrophotometer. The range of wave numbers
was set from 500 to 3000 cm1 and the spectrum was read using
the Happ-Genzel apodisation function over 64 scans with a resolu-
tion of 4 cm1. The region (1575–1750 cm1) which is assigned to
amide I was investigated to determine the secondary structural
changes of SF.
2.6.3. Atomic force microscopy
To obtain the core size and the morphology of the nanocarriers,
Atomic Force Microscopy (AFM) (Dimension Icon with ScanAsyst,
Bruker Corporation, U.S.A) was used. Particle solutions were
dropped on mica substrates and dried with gentle airflow before
placing them on the sample stage, SCANASYST-AIR tips were used
to perform the analysis in dry mode. For the young’s modulus mea-
surement, the nanocarriers were analysed in liquid mode using
FASTSCAN-D with a 5 nm tip radius. The force-distance curves
obtained from the instruments were used to calculate young’s










where F is the force from force curves, E is Young’s modulus, m is
Poisson’s ratio, R is the radius of the indenter tip, and d is the inden-
tation depth. The extracted data were analysed with NanoScope
Analysis 1.9 software.
2.6.4. Transmission electron microscopy
Transmission electron microscopy (TEM) images were obtained
using an FEI Tecnai BioTWIN G2 sprint. The accelerating voltage
was set to 80 Kv. 10 mL of the nanocarrier solution was deposited
onto carbon-coated copper grids for 1 min and blotted with a filter
paper. The grids were then left to dry at 25 C and stained with
0.1% (w/v) phosphotungstic acid for 1 min and then blotted again
with a filter paper. Finally, the samples were washed with DI water
and kept for measurement at room temperature. Images were
recorded using a Gatan Orius SC1000B bottom-mounted digital
camera and Gatan Digital Micrograph software.
2.7. Storage stability
The prepared nanocarriers were stored in a dark place at 4 C for
6 months and their physical stability was monitored by measuring
the changes in particle size during the storage period.
2.8. In vitro drug release
The in vitro drug release profile of the ASC-J9 loaded nanocarrier
solutions was determined by transferring aliquots of ASC-J9
nanocarrier solution (63 mM) into FLOAT-A-LYZER G2 dialysis tub-
ing (MWCO 1000 kDa). The tubes were dialyzed against 50 mL
sodium salicylate solution (1 M) at 37 C with rotation at
150 rpm. The concentration of ASC-J9 released at various time
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points was measured by UV–Vis spectrophotometry at 435 nm.
The drug release profile of the ASC-J9 solution was determined
under identical conditions for comparison. The experiments were
performed in triplicate and the values were reported as mean ± SE.
2.9. Cellular uptake
The cellular uptake studies were carried out using HCT 116
human colorectal adenocarcinoma cells. The cells were cultured
in DMEM supplemented with 10% FBS and 1% penicillin/strepto-
mycin in 37C and under 5% CO2. For the cellular uptake experi-
ments, the HCT 116 cells were cultured in 96 well plates at a
seeding density of 4  103 cells per well and were incubated for
24 h. Then the cells were treated with the drug solution or the
drug-loaded nanocarriers and incubated for 6 h at which point
the media was replaced with fresh media. The experiments were
carried out in two different conditions. The first set of experiments
were performed in the cells growing in DMEM supplemented with
10% FBS. In the second set of experiments, the cells were starved in
serum-free media for 4 h prior to the addition of the drug solution
or drug-loaded nanocarriers and then the media were replaced
with media supplemented with 10% FBS. At designated time points,
the cells were fixed with 3.7% formaldehyde, stained with Hoechst
33,342 and Flash PhalloidinTM 594 and imaged with a high content
fluorescent automated widefield microscope (ImageXpress Micro
System). The images were analysed using MetaXpress software
5.3.01 (Molecular Devices). Two algorithms were used to deter-
mine the cellular uptake: one for quantifying the drug or drug-
loaded objects within the cell, and one for measuring the average
integrated intensity of the drug within the cytosol.
2.10. Uptake in 3D spheroids
The 3D spheroids were prepared by growing HCT 116 cells in
ultra-low attachment 96 well plates at a seeding density of
8  103 cells per well for 48 h. The spheroids were treated with
25 mM ASC-J9 solution or ASC-J9 loaded nanocarriers for 12 h
and then fixed with 3.7% formaldehyde and stained with Hoechst
33,342 and imaged with the high content microscope.
2.11. Statistical analysis
The statistical analysis of the data was carried out using Graph-
Pad Prism 7.04. The Student’s t-test was used for comparison
between two groups, and the one-way ANOVA was used for the
comparison between multiple groups. All experiments were per-
formed in triplicate and the data were presented as the
mean ± standard error of three repeats unless otherwise men-
tioned. Statistical significance was considered when the p value
was less than 0.05.
3. Results & discussion
Due to its strong activity towards cancer cells, curcumin has
been one of the most studied natural compounds for cancer ther-
apy [30]. Recently, curcumin analogues with higher anticancer effi-
cacy such as ASC-J9 have been developed through structural
modifications such as methylation [30,31]. Nonetheless, these
structural changes have led to a tangible increase in the hydropho-
bicity of the resulting drug molecules [32]. ASC-J9 increases the
downstream apoptotic markers to a higher extent compared to
curcumin, which results in enhanced anticancer activity [7]. On
the other hand, ASC-J9 is more hydrophobic than curcumin and
has a relatively short elimination time (t1/2 < 6 h) which limits
its anticancer activity in the tumour tissue [6]. Recently, ASC-J9
was formulated with polymeric nanoparticles (PLGA) to improve
its circulation time and control the drug release [14]. However,
these polymeric formulations do not provide stiffness tunability
and their impact on cellular uptake within the drug elimination
time was not assessed. The present work was aimed at developing
nanocarriers with tuneable properties for enhanced loading,
improved aqueous solubility and enhanced cellular uptake of
ASC-J9 before it is cleared from the body.
3.1. Physical characterization of the ASC-J9 nanocarriers
The designed nanocarriers consist of a lipid bilayer shell and a
biopolymeric core which serves as vector for ASC-J9. Crosslinking
SA with calcium ions within the core transforms the core into a
hydrogel. The rigidity of the resulting hydrogel core is modulated
by blending SA with SF which alters the amount of the SA mono-
mers required to make the hydrogel network (Fig. 1.A). The DOPC
lipid shell provides a template for controlling the overall size of the
nanocarriers via the extrusion method [33]. This shell maintains
the size of the nanocarrier in the aqueous phase as shown in
Fig. 2.A. The DLS characterization showed a similar hydrodynamic
diameter of ~170 nm for all three formulations. The zeta potential
was slightly negative in the nanocarrier formulation SF:SA (3:7).
However, the zeta potential became more negative when the ratio
of SF to SA was increased in the nanocarrier formulation (Fig. 2.C).
Zwitterionic lipids shell (e.g. DOPC) entrapping SA hydrogel has
shown slightly negative zeta potential (4 to 10 mv) [35]. On
the other hand, SF is a negatively charged protein in its b-sheet
form (29 to 43) mv [38] and therefore increasing the ratio of
SF to SA allows more SF molecules to incorporate in the lipid shell
which can explain the reduction in the absolute value of zeta
potential of the SF:SA (7:3). The three nanocarrier formulations
demonstrated size stability for up to 5 months when stored at
4 C (Fig. 2.F). After 6 months, significant variation in the size of
the nanocarriers was observed in the SF:SA (7:3) formulation
which is suspected to be due to aggregation.
The nanocarrier cores were made of multiphase blends of SF
and SA which can exhibit different morphological states. Typically,
dispersing one polymer in the matrix of another induces changes
in the properties of the mixture, and these changes are mainly con-
trolled by the matrix properties [34]. TEM and AFM were used to
provide a clearer insight into the interior structure of the nanocar-
riers. As shown in Fig. 1, spherical nanocarriers were formed in the
three formulations. The dense hydrogel core appears darker than
the lipid bilayer in the TEM image (Fig. 1.B). The AFM scanning
was carried out to determine the morphology of the nanocarriers.
The stiffness of the core correlates to the ratio of SA to SF in the
nanocarrier formulation. The AFM scans revealed that the formula-
tion with the high SF to SA ratio (low stiffness) has an increase in
the core size in comparison to the formulation with the low SF to
SA ratio when scanned in the dry mode (Fig. 1.C & Fig. 2.B). This
can be explained by higher core deformation during scanning
due to less SA hydrogel network which maintains the structure
of the core. The high percentage of SA in the core can form more
hydrogel network after adding the crosslinker, making the
nanocarrier more rigid and less deformable. Different amount of
interfacial water entrapped during the preparation and hydropho-
bic interaction between the two polymers can also play a role in
modifying the deformability of the nanocarriers [39]. The height
profiles obtained by AFM show an increase in the surface rough-
ness of the core structure by increasing the SF to SA ratio (Fig. 1.
E). On the other hand, high SA content provides a smooth core sur-
face because of forming a tighter hydrogel network. The Young’s
modulus was measured using AFM in liquid mode (Fig. 2.G). The
Young’s modulus decreases with the increasing SF:SA ratio, indi-
cating the presence of SF reduced the stiffness of the nanocarriers,
Mhd Anas Tomeh, R. Hadianamrei, W. Sun et al. Journal of Colloid and Interface Science 594 (2021) 513–521
516
which had an implication in drug loading and release
subsequently.
FTIR spectroscopy has been a useful technique to investigate the
transformation of SF to b-sheet structure. The main absorption
peaks for unprocessed SF and SF blends in the nanocarrier formu-
lations are presented in Fig. 3 and Table 1. The FTIR spectrum of
unprocessed SF shows the absorption bands assigned to amide I
(1616.2 cm1) and II (1508.2 cm1) that correspond to b-sheet pre-
dominant conformation (silk II) [27]. Amide III absorption band
(1228.5 cm1) corresponds to silk I conformation with a-helix pre-
dominance. The nanocarrier formulations containing blends of SF
and SA (7:3, 1:1 & 3:7) present spectra similar to the unprocessed
SF with additional absorption bands that are assigned to the C@O,
OAH, and CAO stretching in the SA structure [27,35]. SF amide I
and III absorption bands are overlapping with structural groups
of SA; therefore, the amide II band was used to analyse the spectra
and detect the transformation to silk II. As illustrated in Fig. 3, the
amide II band clearly shifted to a higher wavelength and was
detected at 1528.2 cm1 indicating silk II conformation.
3.2. ASC-J9 encapsulation and release
Drug encapsulation efficiency is one of the most important fea-
tures for determining the effectiveness of the designed delivery
Fig. 1. (A) Schematic representation of the three types of synthesized nanocarriers, entrapping silk fibroin (SF) and sodium alginate (SA) cores (at different SF/SA ratios) in the
lipid shells. (B) TEM images of the synthesized nanocarriers. (C) AFM images of the nanocarriers showing the polymeric core and the lipid shell in dry mode. (D) 3D AFM
images of the nanocarriers. (E) Hight profiles of the nanocarriers obtained by AFM.
Fig. 2. Characterization of the synthesized nanocarrier formulations with varying properties. (A) Particle size of the nanocarriers measured by dynamic light scattering (DLS).
(B) Core size of the nanocarriers obtained by AFM scans in dry mode. (C) Zeta potential of the nanocarriers measured by DLS. (D) Encapsulation efficiency (EE) of ASC-J9 in
different nanocarrier formulations. (E) Release profiles of ASC-J9 encapsulated in different nanocarrier formulations. (F) Changes to the diameters of nanocarriers over
6 months measured by DLS. (G) The Young’s moduli of the nanocarriers characterized in liquid mode by AFM. (H) Schematic illustration of high and low stiffness nanocarriers
during Young’s moduli measurements in AFM. * Denotes values of P < 0.05.
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system as a drug carrier especially in nanoformulations [20]. For
efficient entrapment of ASC-J9 in the polymeric core matrix, the
drug and the crosslinking agent (CaCl2) were added simultane-
ously. The drug molecule enters the matrix with calcium ions that
are transforming the structure of SA to form the hydrogel network.
Changing the nature of the core from liquid state to polysaccharide
hydrogel during crosslinking can restrict the Brownian motion of
the ASC-J9 molecules and enhance their retention in the nanocar-
rier. A previous study has shown a significant increase in encapsu-
lation efficiency as a result of hydrogel network formation.
However, no significant change in EEs was observed in different
hydrogel stiffness when one polymer was used [28]. In the current
study, two polymers (SF & SA) have been used and the interaction
between the two during crosslinking allows SF to transform to b
sheet providing a platform for hydrophobic interaction with ASC-
J9 molecules. This can explain the higher EE observed in high SF
content nanocarrier formulation (SF:SA 7:3) in comparison to the
formulation with lower SF content (SF:SA 1:1, 3:7) (Fig. 2.D).
The effect of modifying the nanocarrier stiffness on the drug
release kinetics was also investigated. The nanocarrier formulation
with higher stiffness (higher modulus) exhibited slower drug
release (Fig. 2.E). The high percentage of SA results in a tighter
hydrogel network and smaller pore size (Fig. 1.D&E) which conse-
quently results in higher retention and slower release of the encap-
sulated drug (Fig. 2. D). These results suggest enhanced EE and
tunable drug release achieved by modification of the nanocarrier
core composition.
3.3. In vitro cellular uptake study
The designed nanocarriers consist of a combination of biopoly-
mers that are individually approved by the FDA for pharmaceutical
applications and regarded as biocompatible, nonimmunogenic, and
nontoxic polymers [28,40]. To confirm the lack of toxicity of the
unloaded nanocarrier formulations, the cell population was evalu-
ated after treatment with unloaded nanocarriers (SF:SA 7:3, 1:1 &
3:7) (Fig. 5.D). The reduction in the cell population ranged between
1 and 11% indicating very low toxicity.
To investigate the internalization of the nanocarriers and their
payload release in HCT 116 colorectal adenocarcinoma cells, the
cells were treated with ASC-J9 (25 mM) or ASC-J9 loaded nanocar-
riers for 6 h to simulate the drug availability time in vivo before
elimination. The experiments were carried out in two conditions
(10% FBS & 0% FBS) to mimic different in vivo physiological condi-
tions. The treatments were removed after 6 h by replacing the
media to ensure that the intensity measurements are assigned only
to the uptaken drug. Like curcumin, the ASC-J9 molecule is auto-
fluorescent ((kexc = 420 nm; kemi = 522 nm) and this property has
been used previously for cell tracking and measuring cellular
uptake [14,15,41]. The enhanced cellular uptake by HCT 116 cells
is evident from the high content images presented in Fig. 4. A
weaker fluorescent signal was observed in cells treated with
unprocessed ASC-J9 in comparison to ASC-J9 loaded nanocarriers.
As it could be observed in Fig. 5 the relative uptake of the ASC-J9
was significantly enhanced when it was loaded into the different
nanocarrier formulations. Moreover, the ASC-J9-loaded nanocarri-
ers remained in the cells for up to 72 h after internalization serving
as a reservoir for the drug and providing sustained drug release
whereas the amount of free ASC-J9 within the cells showed a
reduction after 72 h. This is supposed to be due to cellular efflux
mediated by transporters such as P-glycoprotein [9].
The anticancer activity of the drug was assessed by measuring
the percentage of cells within a population that survived after
treatment with the free drug and the drug-loaded nanocarriers at
different time points (Fig. 5.C). The free ASC-J9 showed higher
activity at 12 h than the drug-loaded into the nanocarriers, causing
a 50–60% reduction in the number of cancer cells. However, due to
the low concentration of the drug within the cells resulting from
lower cellular uptake compared to the drug-loaded nanocarriers,
the cells recovered from the drug treatment and restarted growing
after 24 h. In the case of drug-loaded nanocarriers, the antiprolifer-
ative activity started more slowly but was maintained over a
longer period of time (72 h) resulting in a considerable reduction
in the cell population (Fig. 5.C). A variation in the anticancer activ-
ity was observed among the three nanocarrier formulations at 12 h
especially in the absence of FBS. However, all nanocarriers formu-
lations showed a similar pattern after 24 h. This behaviour can be
explained by the different drug release trend exerted by different
formulations. Overall, it can be conferred from these data that
Fig. 3. (A) Schematic representation of silk fibroin (SF) structural transforamtion in the designed nanocarries as a result of blending with sodium alginate (SA). (B) FTIR
spectra of SF and SF/SA blends with different ratio in the nanocarrier core.
Table 1







Attribution of absorption peaks
– 1731.9 1731.9 C@O stretching
1620.1 1622.0 1635.5 Amide I and
antisymmetric = COO = stretching overlap
1505.2 1522.0 – Amide II
1228.5 1236.2 1238.2 Amide III and C@O stretching overlap
– 1080.0 1076.2 OAH bending
– 1029.9 1027.9 OAH bending
– 927.7 927.7 CAO vibration
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the anticancer activity of the ASC-J9 in HCT 116 cells was enhanced
by loading into the designed nanocarriers and that the sustained
release of the drug from the nanocarriers resulted in a prolonged
antiproliferative activity which prevented the cells from
recovering.
3.4. Uptake in 3D tumour spheroids
3D tumour spheroids were used as a mimic of the tumours in
order to provide a better insight into the drug interaction with
the tumour cells as they provide a closer simulation of the tumour
Fig. 4. High content fluorescent microscope images of HCT 116 showing cellular uptake of the free ASC-J9 and different ASC-J9 loaded nanocarriers (SF:SA = 7:3, 1:1, & 3:7)
after 24 h (20 magnification, the scale bar represents 40 mm).
Fig. 5. (A) Relative cellular uptake of ASC-J9 loaded nanocarriers formulations and unformulated ASC-J9. (B) Fluorescence integrated intensity of ASC-J9 at multiple time
points in unformulated form and in nanocarriers form. (C) The percentage of survived cells after ASC-J9 and ASC-J9 loaded nanocarriers treatments at multiple time points.
(D) The effect of the unloaded nanocarrier formulations to the cell population. An asterisk denotes statistical significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001.
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than the 2D cell culture. [42,43]. Spheroids generated form HCT
116 cells (with a diameter of 600–800 mm) were used to assess
the penetration and anticancer effect of the ASC-J9 loaded on the
designed nanocarriers into the tumours. The tumour penetration
study using the mean fluorescence intensity was previously
reported [44]. As it could be clearly observed in Fig. 6.A, the drug
fluorescence appears to be quite uniformly distributed across the
spheroids. A drastic increase in the fluorescence intensity was
detected in the spheroids treated with ASC-J9 loaded nanocarriers
in comparison to the spheroids treated with the free drug. Further-
more, there was a significant difference in the fluorescence inten-
sity of the drug within the spheroids treated with different
nanocarrier formulations (Fig. 6.B). The SF:SA (7:3) formulation
(with low stiffness) had the highest fluorescence intensity followed
by SF:SA (1:1) and SF:SA (3:7) respectively. The observed differ-
ence in the drug penetration into tumour spheroids is attributed
to the different elasticity of the nanocarrier formulations providing
a tool for tuning the cellular uptake of the drug-loaded nanocarri-
ers through changing the composition of the nanocarrier cores.
4. Conclusion
SF is a biocompatible biopolymer which has been approved by
FDA for pharmaceutical applications. Therefore, it has gained great
attention as the main ingredient in various drug delivery systems.
Although the nature of SF protein is desirable, formulating SF as
stable nanocarriers with controllable properties remains a chal-
lenge. Herein, we report the development of a very versatile, stable
nanocarrier system using a blend of SF and SA in a lipid template
for enhanced encapsulation and controlled release of the
hydrophobic anticancer agent ASC-J9. The designed nanocarriers
were prepared using a simple method that avoids harsh prepara-
tion conditions such as extreme heat, pH or organic solvents and
enjoyed controllable size (using the extruded lipid template tech-
nique) and tunable stiffness (via changing the SF/SA ratio). The pre-
sented technique addresses the common limitations in formulating
protein-based nanostructures such as lack of controllability of size
and shape [15]. In addition, tuning the stiffness of the nanocarriers
resulted in changes to the drug release and anticancer activity of
the ASC-J9 in HCT 116 colorectal cancer cells. Our findings also dis-
play for the first time a significant increase in cellular uptake of
ASC-J9 within its t1/2 window when loaded into the nanocarrier
systems and a prolonged anticancer activity resulting in the pre-
vention of the colorectal cancer cell recovery in comparison to
the free drug which may be of significance in preventing MDR.
Modifying the nanocarrier properties also affected their penetra-
tion into the 3D tumour spheroids which serve as a model for solid
tumours. Despite the large number of factors that govern the
mechanism of cellular uptake in tumours, the results of this study
suggest that tailoring the stiffness of the anticancer nanocarriers
should be considered in the rational design of anticancer drug
delivery systems.
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